Zachary Zimmerman | CEO
Forge Therapeutics

Zachary Zimmerman, CEO, Forge Therapeutics

Founder and CEO of Forge Therapeutics Inc with over 15+ years of start-up experience in business leadership roles at Arcturus Therapeutics (private), Regulus Therapeutics (NASDAQ:RGLS), Alnylam Pharmaceuticals (NASDAQ:ALNY).  Successfully driven company growth through strategic alliances, financings, and non-dilutive grant awards totaling $3.2 billion with over $200 million in upfront cash payments

Appearances:



World Anti-Microbial Resistance Congress USA 2018 - Day 1 @ 17:30

Keynote CEO Panel: How to do business in a challenging environment - Current landscape for biotechs looking to commercialize or commercializing antimicrobials

  • How do you turn the current antibiotic development and commercialization model into one that is attractive to big pharma
  • Partnering and business development opportunities for smaller antibiotic biotechs – overcoming low stock prices
  • How can developing companies survive in this space and get continuous investments? Is the emergence of smaller companies the way to commercial viability and efficient distribution of resources
  • What is the investment landscape going to look like for up and coming companies
  • How to launch a product and demonstrate commercial success

World Anti-Microbial Resistance Congress USA 2018 - Day 2 @ 15:10

Forging innovation: leveraging credible funding and partnerships for novel class antibiotic pipeline expansion

  • Beyond grant funding: taking advantage of CARB-X due diligence and scientific approach to advance Forge’s metalloenzymes
  • How can strategic early stage partnerships for lead optimization and susceptibility testing gain the interest of investors?
  • Expanding pipeline to include multiple new novel class antibiotics
last published: 12/Oct/18 20:55 GMT

back to speakers